The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis
Open accessAbstract
Objective: Sodium glucose cotransporter 2 (SGLT2) inhibitors may induce urinary glucose excretion via the inhibition of renal glucose reabsorption, improve glycemic control, and lower body weight. The aim of this meta‐analysis was to evaluate weight changes in patients who received different dosages of SGLT2 inhibitors. Methods: Overall, 55 placebo‐controlled trials were included. Results: The results indicated that treatment with 2.5 mg, 5 mg, 10 mg, and 20 mg of dapagliflozin led to significant decreases in body weight compared with a placebo (weighted mean difference [WMD], −1.30 kg, −1.51 kg, −1.79 kg, −2.24 kg, respectively; P < 0.001). Treatment with 50 mg, 100 mg, 200 mg, and 300 mg of canagliflozin also led to significant decreases in weight (WMD, −1.20 kg, −1.82 kg, −1.83 kg, −2.37 kg, respectively; P < 0.001). In the treatment with empagliflozin, ipragliflozin, tofogliflozin, and luseogliflozin, body weight also significantly decreased. The decrease in weight was associated with the dosage of dapagliflozin (P < 0.05). Conclusions: Body weight significantly decreased in patients with type 2 diabetes who received different dosages of SGLT2 inhibitors compared with patients who received a placebo. Moreover, in patients treated with dapagliflozin, there was a statistically significant dosage‐dependent trend in body weight reduction.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Combinational approaches of incretin (co)agonists with diet and exercise may be superior strategies for sustainable weight loss compared to sole drug treatment.
“Moreover, although providing undoubtedly impressive effects on body weight, combinational approaches of incretin (co)agonists with diet and exercise may be superior strategies for sustainable weight loss compared to sole drug treatment [144,145].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [145]
The Introduction and Discussion report that GLP-1 agonists, including liraglutide, are associated with weight loss. They do not address whether combining incretin agonists with diet and exercise produces more sustainable weight loss than drug treatment alone; the paper’s meta-analysis concerns SGLT2 inhibitor dosage. (LLM, conf=0.79)
Experimental — accuracy not yet measuredThe weight reduction from SGLT2 inhibitors is limited among patients with type 2 diabetes.
“Meta-analyses of the SGLT2 inhibitors dapagliflozin, canagliflozin, empagliflozin, ipragliflozin, tofogliflozin, and luseogliflozin support modest body weight reduction (∼1–2 kg), but the weight reduction is limited among patients with type 2 diabetes [107].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [107]
Meta-analyses of the SGLT2 inhibitors dapagliflozin, canagliflozin, empagliflozin, ipragliflozin, tofogliflozin, and luseogliflozin support modest body weight reduction of about 1-2 kg.
“Meta-analyses of the SGLT2 inhibitors dapagliflozin, canagliflozin, empagliflozin, ipragliflozin, tofogliflozin, and luseogliflozin support modest body weight reduction (∼1–2 kg), but the weight reduction is limited among patients with type 2 diabetes [107].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [107]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817 · see citing works
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164 · see citing works
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · see citing works
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · see citing works
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919 · see citing works
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207 · see citing works
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · see citing works
(2) Classification and diagnosis of diabetes
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc15-s005 · Cited by 1,841 · see citing works
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198 · see citing works
Quantification of the effect of energy imbalance on bodyweight
Hall, K. D., Sacks, G., Chandramohan, D., Chow, C. C., Wang, Y. C., Gortmaker, S. L., & Swinburn, B. A. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60812-x · Cited by 1,165 · see citing works
Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867 · see citing works
Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A., & List, J. F. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60407-2 · Cited by 861 · see citing works
Cefalu, W. T., Leiter, L. A., Yoon, K., Arias, P., NISKANEN, L. K., Xie, J., Balis, D. A., Canovatchel, W. J., & Meininger, G. E. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60683-2 · Cited by 723 · see citing works
Ferrannini, E., Ramos, S. J., Salsali, A., Tang, W., & List, J. F. (2010) · Diabetes Care · doi:10.2337/dc10-0612 · Cited by 719 · see citing works
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
List, J. F., Woo, V., Morales, E., Tang, W., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc08-1863 · Cited by 698 · see citing works
Stenlöf, K., Cefalu, W. T., Kim, K., Alba, M., Usiskin, K., Tong, C., Canovatchel, W. J., & Meininger, G. E. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12054 · Cited by 613 · see citing works
Barnett, A. H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H. J., & Broedl, U. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70208-0 · Cited by 575 · see citing works
Lavalle-Gonzalez, F. J., Januszewicz, A., Davidson, J. A., Tong, C., Qiu, R., Canovatchel, W. J., & Meininger, G. E. (2013) · Diabetologia · doi:10.1007/s00125-013-3039-1 · Cited by 492 · see citing works
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
Yale, J., Bakris, G. L., Cariou, B., Yue, D. K., David‐Neto, E., Xi, L., Figueroa, K., Wajs, E., Usiskin, K., & Meininger, G. E. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12090 · Cited by 485 · see citing works
Wilding, J. P. H., Woo, V., Soler, N. G., Pahor, A., Sugg, J., Rohwedder, K., Parikh, S., & for the Dapagliflozin 006 Study Group* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-6-201203200-00003 · Cited by 469 · see citing works
Roden, M., Weng, J., Eilbracht, J., Delafont, B., Kim, G., Woerle, H. J., & Broedl, U. C. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70084-6 · Cited by 451 · see citing works
Rosenstock, J., Aggarwal, N., Polidori, D., Zhao, Y., Arbit, D. I., Usiskin, K., Capuano, G. A., Canovatchel, W. J., & for the Canagliflozin DIA 2001 Study Group (2012) · Diabetes Care · doi:10.2337/dc11-1926 · Cited by 421 · see citing works
Rosenstock, J., Vico, M. L., Wei, L., Salsali, A., & List, J. F. (2012) · Diabetes Care · doi:10.2337/dc11-1693 · Cited by 409 · see citing works
Strojek, K., Yoon, K., Hrubá, V., Elze, M., Langkilde, A. M., & Parikh, S. J. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01434.x · Cited by 407 · see citing works
Häring, H., Merker, L., Seewaldt-Becker, E., Weimer, M. S., Meinicke, T. W., Broedl, U. C., Woerle, H. J., & on behalf of the EMPA-REG MET Trial Investigators (2014) · Diabetes Care · doi:10.2337/dc13-2105 · Cited by 401 · see citing works
Komoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D., & Pfister, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.250 · Cited by 396 · see citing works
Kovács, C. S., Seshiah, V., Swallow, R., Jones, R., Rattunde, H., Woerle, H. J., Broedl, U. C., & on behalf of the EMPA‐REG PIO™ trial investigators (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12188 · Cited by 389 · see citing works
Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes
Häring, H., Merker, L., Seewaldt-Becker, E., Weimer, M. S., Meinicke, T. W., Woerle, H. J., Broedl, U. C., & on behalf of the EMPA-REG METSU Trial Investigators (2013) · Diabetes Care · doi:10.2337/dc12-2673 · Cited by 374 · see citing works
Rosenstock, J., Jelaska, A., Frappin, G., Salsali, A., Kim, G., Woerle, H. J., & Broedl, U. C. (2014) · Diabetes Care · doi:10.2337/dc13-3055 · Cited by 366 · see citing works
Wilding, J. P. H., Norwood, P. C., T'joen, C., Bastien, A., List, J. F., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc09-0517 · Cited by 362 · see citing works
Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
Komoroski, B., Vachharajani, N., Boulton, D., Kornhauser, D., Geraldes, M., Li, L., & Pfister, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.251 · Cited by 350 · see citing works
SGLT inhibitors in management of diabetes
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70050-0 · Cited by 333 · see citing works
Henry, R. R., Murray, A. V., Marmolejo, M. H., Hennicken, D., Ptaszynska, A., & List, J. F. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02911.x · Cited by 312 · see citing works
Rosenstock, J., Hansen, L., Zee, P., Li, Y., Cook, W., Hirshberg, B., & Iqbal, N. (2014) · Diabetes Care · doi:10.2337/dc14-1142 · Cited by 291 · see citing works
The Prevention and Treatment of Obesity: Application to type 2 diabetes
Maggio, C. A., & Pi-Sunyer, X. (1997) · Diabetes Care · doi:10.2337/diacare.20.11.1744 · Cited by 261 · see citing works
Weber, M. A., Mansfield, T. A., Cain, V. A., Iqbal, N., Parikh, S. J., & Ptaszynska, A. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00417-9 · Cited by 255 · see citing works
Forst, T. M., Guthrie, R. M., Goldenberg, R., Yee, J., Vijapurkar, U., Meininger, G. E., & Stein, P. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12273 · Cited by 254 · see citing works
Sha, S., Polidori, D., Heise, T., Natarajan, J., Farrell, K., Wang, S. ‐., Sica, D., Rothenberg, P., & Plum‐Mörschel, L. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12322 · Cited by 249 · see citing works
The obesity paradox, weight loss, and coronary disease
Lavie, C. J., Milani, R. V., Artham, S. M., Patel, D. A., & Ventura, H. O. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.06.006 · Cited by 237 · see citing works
Neal, B., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Ways, K., Desai, M., Shaw, W., Capuano, G., Alba, M., et al. (2015) · Diabetes Care · doi:10.2337/dc14-1237 · Cited by 233 · see citing works
Bode, B. W., Stenlöf, K., Harris, S. B., Sullivan, D., Fung, A., Usiskin, K., & Meininger, G. E. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12428 · Cited by 228 · see citing works
Blonde, L., & Russell-Jones, D. L. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01075.x · Cited by 227 · see citing works
Devineni, D., Morrow, L., Hompesch, M., Skee, D. M., Vandebosch, A., Murphy, J., Ways, K., & Schwartz, S. L. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01558.x · Cited by 219 · see citing works
Ljunggren, Ö., Bolinder, J., Johansson, L., Wilding, J. P. H., Langkilde, A. M., Sjöström, C. D., Sugg, J. E., & Parikh, S. J. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01630.x · Cited by 216 · see citing works
Kaku, K., Watada, H., Iwamoto, Y., Utsunomiya, K., Terauchi, Y., Tobe, K., Tanizawa, Y., Araki, E., Ueda, M., Suganami, H., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-65 · Cited by 212 · see citing works
Leiter, L. A., Cefalu, W. T., de Bruin, T. W., Gause‐Nilsson, I. A. M., Sugg, J. E., & Parikh, S. J. (2014) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12881 · Cited by 183 · see citing works
Cefalu, W. T., Leiter, L. A., de Bruin, T. W. A., Gause-Nilsson, I., Sugg, J., & Parikh, S. J. (2015) · Diabetes Care · doi:10.2337/dc14-0315 · Cited by 182 · see citing works
Ferrannini, E., SEMAN, L. J., Seewaldt-Becker, E., Hantel, S., Pinnetti, S., & Woerle, H. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12081 · Cited by 181 · see citing works
Ji, L., Ma, J., Li, H., Mansfield, T. A., T'joen, C., Iqbal, N., Ptaszynska, A., & List, J. F. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.11.002 · Cited by 171 · see citing works
Self-citationWilding, J. P. H. (2014) · Metabolism · doi:10.1016/j.metabol.2014.06.018 · Cited by 169 · see citing works
Bailey, C. J., Iqbal, N., T'joen, C., & List, J. F. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01659.x · Cited by 168 · see citing works
Bailey, C. J., Villegas, E. C. M., Woo, V. C., Tang, W., Ptaszynska, A., & List, J. F. (2014) · Diabetic Medicine · doi:10.1111/dme.12624 · Cited by 153 · see citing works
Mathieu, C., Ranetti, A.-E., Li, D., Ekholm, E., Cook, W., Hirshberg, B., Chen, H., Hansen, L., & Iqbal, N. (2015) · Diabetes Care · doi:10.2337/dc15-0779 · Cited by 149 · see citing works
Matthaei, S., Bowering, K., Rohwedder, K., Grohl, A., Parikh, S. J., & for the Study 05 Group (2015) · Diabetes Care · doi:10.2337/dc14-0666 · Cited by 149 · see citing works
Seino, Y., Sasaki, T., Fukatsu, A., Ubukata, M., Sakai, S., & Samukawa, Y. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.912983 · Cited by 143 · see citing works
Inagaki, N., Kondo, K., Yoshinari, T., Maruyama, N., Susuta, Y., & Kuki, H. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12149 · Cited by 136 · see citing works
Kaku, K., Inoue, S., Matsuoka, O., Kiyosue, A., Azuma, H., Hayashi, N., Tokudome, T., Langkilde, A. M., & Parikh, S. J. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12047 · Cited by 136 · see citing works
On behalf of the EMPA-REG EXTEND™ MONO investigators, Roden, M., Merker, L., Christiansen, A. V., Roux, F., Salsali, A., Kim, G., Stella, P., Woerle, H. J., & Broedl, U. C. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0314-0 · Cited by 127 · see citing works
Inagaki, N., Kondo, K., Yoshinari, T., Takahashi, N., Susuta, Y., & Kuki, H. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.935764 · Cited by 124 · see citing works
Kashiwagi, A., Takahashi, H., Ishikawa, H., Yoshida, S., Kazuta, K., Utsuno, A., & Ueyama, E. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12403 · Cited by 117 · see citing works
Wilding, J. P. H., Ferrannini, E., Fonseca, V. A., Wilpshaar, W., Dhanjal, P., & Houzer, A. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12038 · Cited by 117 · see citing works
Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes
Hadjadj, S., Rosenstock, J., Meinicke, T. W., Woerle, H. J., & Broedl, U. C. (2016) · Diabetes Care · doi:10.2337/dc16-0522 · Cited by 115 · see citing works
Kashiwagi, A., Kazuta, K., Goto, K., Yoshida, S., Ueyama, E., & Utsuno, A. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12331 · Cited by 102 · see citing works
Ji, L., Han, P., Liu, Y., Yang, G., Van, N. K. D., Vijapurkar, U., Qiu, R., & Meininger, G. E. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12385 · Cited by 87 · see citing works
Self-citationFonseca, V. A., Ferrannini, E., Wilding, J. P. H., Wilpshaar, W., Dhanjal, P., Ball, G., & Klasen, S. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.11.005 · Cited by 86 · see citing works
Empagliflozin as add‐on to metformin in people with Type 2 diabetes
Merker, L., Häring, H.-U., Christiansen, A. V., Roux, F., Salsali, A., Kim, G.-H., Meinicke, T. W., Woerle, H. J., Broedl, U. C., & the EMPA‐REG EXTEND MET investigators (2015) · Diabetic Medicine · doi:10.1111/dme.12814 · Cited by 83 · see citing works
Haneda, M., Seino, Y., Inagaki, N., Kaku, K., Sasaki, T., Fukatsu, A., Kakiuchi, H., Sato, Y. A., Sakai, S., & Samukawa, Y. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.10.025 · Cited by 82 · see citing works
Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes
Haering, H.-U., Merker, L., Christiansen, A. V., Roux, F., Salsali, A., Kim, G., Meinicke, T. W., Woerle, H. J., & Broedl, U. C. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.05.044 · Cited by 80 · see citing works
Ikeda, S., Takano, Y., Cynshi, O., Tanaka, R., Christ, A. D., Boerlin, V., Beyer, U., Beck, A., Ciorciaro, C., Meyer, M., et al. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12538 · Cited by 73 · see citing works
Sha, S., Devineni, D., Ghosh, A., Polidori, D., Hompesch, M., Arnolds, S., Morrow, L., Spitzer, H., Demarest, K. T., & Rothenberg, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105638 · Cited by 71 · see citing works
Lu, C., Min, K. W., Chuang, L., Kokubo, S., Yoshida, S., & Cha, B. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12422 · Cited by 67 · see citing works
Seino, Y., Sasaki, T., Fukatsu, A., Sakai, S., & Samukawa, Y. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.901943 · Cited by 64 · see citing works
Schumm‐Draeger, P. ‐., Burgess, L. J., Koranyi, L. I., Hrubá, V., Hamer-Maansson, J. E., & de Bruin, T. W. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12387 · Cited by 63 · see citing works
Seino, Y., Sasaki, T., Fukatsu, A., Ubukata, M., Sakai, S., & Samukawa, Y. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.909390 · Cited by 61 · see citing works
Seino, Y., Inagaki, N., Haneda, M., Kaku, K., Sasaki, T., Fukatsu, A., Ubukata, M., Sakai, S., & Samukawa, Y. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12316 · Cited by 54 · see citing works
Ross, S., Thamer, C., Cescutti, J., Meinicke, T. W., Woerle, H. J., & Broedl, U. C. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12469 · Cited by 50 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
Lopaschuk, G. D., & Verma, S. (2020) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2020.02.004 · Cited by 914 · see citing works
The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
Thomas, M. C., & Cherney, D. Z. I. (2018) · Diabetologia · doi:10.1007/s00125-018-4669-0 · Cited by 351 · see citing works
Młynarska, E., Czarnik, W., Kurys, N., Jędraszak, W., Majchrowicz, G., Prusinowski, F., Stabrawa, M., Rysz, J., & Franczyk, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031094 · Cited by 421 · see citing works
Bonnet, F., & Scheen, A. J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.09.005 · Cited by 311 · see citing works
Emerging role of SGLT-2 inhibitors for the treatment of obesity
Pereira, M. J., & Eriksson, J. W. (2019) · Drugs · doi:10.1007/s40265-019-1057-0 · Cited by 342 · see citing works
Pharmacotherapy of obesity: available medications and drugs under investigation.
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248 · see citing works
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
Bailey, C. J., Day, C., & Bellary, S. (2022) · Current Diabetes Reports · doi:10.1007/s11892-021-01442-z · Cited by 257 · see citing works
Lee, P. C., Ganguly, S., & Goh, S. ‐. (2018) · Obesity Reviews · doi:10.1111/obr.12755 · Cited by 189 · see citing works
Hierro‐Bujalance, C., Infante‐Garcia, C., del Marco, À., Herrera, M., Carranza-Naval, M. J., Suarez, J., Alves-Martínez, P., Lubián‐López, S. P., & Garcı́a-Alloza, M. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00607-4 · Cited by 186 · see citing works
SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
Ανδρουτσάκος, Θ., Ansari, N. N., Bakasis, A., Kyrou, I., EFSTATHOPOULOS, E. P., Randeva, H. S., & Kassi, E. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063107 · Cited by 172 · see citing works
Liu, Z., Ma, X., Ilyas, I., Zheng, X., Luo, S., Little, P. J., Kamato, D., Sahebkar, A., Wu, W., Weng, J., et al. (2021) · Theranostics · doi:10.7150/thno.54498 · Cited by 155 · see citing works
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Huttasch, M., Roden, M., & Kahl, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155937 · Cited by 169 · see citing works
Scheen, A. J. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.01.008 · Cited by 146 · see citing works
Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
Angelidi, A. M., Belanger, M. J., Kokkinos, A. D., Koliaki, C. C., & Mantzoros, C. S. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab034 · Cited by 133 · see citing works
Bariatric Surgery in the Treatment of Type 2 Diabetes
Affinati, A. H., Esfandiari, N. H., Oral, E. A., & Kraftson, A. T. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1269-4 · Cited by 125 · see citing works
Applications of SGLT2 inhibitors beyond glycaemic control
O’Hara, D. V., Lam, C. S. P., McMurray, J. J. V., Yi, T. W., HOCKING, S. L., Dawson, J., Raichand, S., Januszewski, A. S., & Jardine, M. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00836-y · Cited by 111 · see citing works
SGLT inhibitors on weight and body mass: A meta‐analysis of 116 randomized‐controlled trials
Cheong, A. J. Y., Teo, Y. N., Teo, Y. H., Syn, N. L. X., Ong, H. T., Ting, A. Z. H., Chia, A. Z. Q., Chong, E. Y., Chan, M. Y., Lee, C., et al. (2021) · Obesity · doi:10.1002/oby.23331 · Cited by 101 · see citing works
Yaribeygi, H., Sathyapalan, T., Maleki, M., Jamialahmadi, T., & Sahebkar, A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117090 · Cited by 94 · see citing works
Dong, M., Wen, S., & Zhou, L. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s375559 · Cited by 90 · see citing works
Self-citationGiorgino, F., Vora, J. P., Fenici, P., & Solini, A. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01163-9 · Cited by 85 · see citing works
Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68 · see citing works
SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD
Ala, M. (2021) · Endocrinology · doi:10.1210/endocr/bqab157 · Cited by 71 · see citing works
Obesity and Breast Cancer Risk: The Oncogenic Implications of Metabolic Dysregulation
Naaman, S., Shen, S., Zeytinoglu, M., & Iyengar, N. M. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac241 · Cited by 66 · see citing works
Renal physiology of glucose handling and therapeutic implications
Cherney, D. Z. I., Kanbay, M., & Lovshin, J. A. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz230 · Cited by 66 · see citing works
Bamba, R., Okamura, T., Hashimoto, Y., Majima, S., Senmaru, T., Ushigome, E., Nakanishi, N., Asano, M., Yamazaki, M., Takakuwa, H., et al. (2021) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12814 · Cited by 61 · see citing works
Anker, S. D., Khan, M. S., Butler, J., Ofstad, A. P., Peil, B., Pfarr, E., Doehner, W., Sattar, N. A., Coats, A. J. S., Filippatos, G. S., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2728 · Cited by 60 · see citing works
Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus
Zhang, R., Xie, Q., Lu, X., Fan, R., & Tong, N. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01325-9 · Cited by 57 · see citing works
Pathophysiology and Treatment of Prediabetes and Type 2 Diabetes in Youth
Bacha, F. F., Hannon, T. S., Tosur, M., Pike, J. M., Butler, A. M., Tommerdahl, K. L., & Zeitler, P. S. (2024) · Diabetes Care · doi:10.2337/dci24-0029 · Cited by 59 · see citing works
Highlights of mechanisms and treatment of obesity-related hypertension
Shams, E., Kamalumpundi, V., Peterson, J., Gismondi, R. A., Oigman, W., & Correia, M. (2022) · Journal of Human Hypertension · doi:10.1038/s41371-021-00644-y · Cited by 57 · see citing works
Butler, J., Handelsman, Y., Bakris, G. L., & Verma, S. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1708 · Cited by 52 · see citing works
Sheu, W. H., Chan, S. P., Matawaran, B. J., Deerochanawong, C., Mithal, A., Chan, J. C. N., Suastika, K., Khoo, C. M., Nguyen, H. M., Ji, L., et al. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0208 · Cited by 52 · see citing works
Self-citationWang, X., Wu, N., Sun, C., Jin, D., & Lu, H. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01085-y · Cited by 50 · see citing works
Coats, A. J. S., Butler, J., Tsutsui, H., Doehner, W., Filippatos, G. S., Ferreira, J. P., Böhm, M., Chopra, V., Verma, S., Nordaby, M., et al. (2023) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13393 · Cited by 46 · see citing works
Oh, T. J., Sul, W. J., Oh, H. N., Lee, Y.-K., Lim, H. L., Choi, S. H., Park, K. S., & Jang, H. C. (2019) · Scientific Reports · doi:10.1038/s41598-019-56684-5 · Cited by 45 · see citing works
Cai, M., Shao, X., Xing, F., Zhang, Y., Gao, X., Zeng, Q., Dilimulati, D., Qu, S., & Zhang, M. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14583 · Cited by 44 · see citing works
Self-citationCho, Y. K., Kim, Y., & Jung, C. H. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21061 · Cited by 45 · see citing works
Nesti, L., Pugliese, N. R., Sciuto, P., Tricò, D., Dardano, A., Baldi, S., Pinnola, S., Fabiani, I., Bello, V. D., & Natali, A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01618-1 · Cited by 43 · see citing works
Weight-centric treatment of type 2 diabetes mellitus
Ghusn, W., Hurtado, M. D., & Acosta, A. J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100045 · Cited by 41 · see citing works
Scheen, A. J. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s193528 · Cited by 36 · see citing works
SGLT2 inhibitors, an Accomplished Development in Field of Medicinal Chemistry: an Extensive Review
Manoj, A., Das, S., Ramachandran, A. K., Alex, A. T., & Joseph, A. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0154 · Cited by 36 · see citing works
Associated factors and principal pathophysiological mechanisms of type 2 diabetes mellitus
Wang, L., Li, L., Liu, J., Sheng, C., Yang, M., Hu, Z., & Yue, R. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1499565 · Cited by 43 · see citing works
SGLT2 inhibition to address the unmet needs in diabetic nephropathy
Barutta, F., Bernardi, S., Gargiulo, G., Durazzo, M., & Gruden, G. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3171 · Cited by 35 · see citing works
Iordan, L., Gaiţă, L., Timar, R. Z., Avram, V. F., Sturza, A., & Timar, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137057 · Cited by 33 · see citing works
Sasaki, A., Yokote, K., Naitoh, T., Fujikura, J., Hayashi, K., Hirota, Y., Inagaki, N., Ishigaki, Y., Kasama, K., Kikkawa, E., et al. (2021) · Diabetology International · doi:10.1007/s13340-021-00551-0 · Cited by 33 · see citing works
Jiang, A., Feng, Z., Yuan, L., Zhang, Y., Li, Q., & She, Y. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00652-5 · Cited by 31 · see citing works
Xie, L., & Wenfang, X. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120543 · Cited by 33 · see citing works
Wen, S., Nguyen, T., Gong, M., Yuan, X., Wang, C., Jin, J., & Zhou, L. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s312527 · Cited by 32 · see citing works
Self-citationTargeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition
Herat, L. Y., Matthews, J. R., Azzam, O., Schlaich, M. P., & Matthews, V. B. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01170-z · Cited by 30 · see citing works
The major molecular mechanisms mediating the renoprotective effects of SGLT2 inhibitors: An update
Yaribeygi, H., Simental‐Mendía, L. E., Banach, M., Bo, S., & Sahebkar, A. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109526 · Cited by 29 · see citing works
Kubota, Y., & Shimizu, W. (2022) · JACC Asia · doi:10.1016/j.jacasi.2022.03.009 · Cited by 29 · see citing works
The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
Koutentakis, M., Kuciński, J., Świeczkowski, D., Surma, S., Filipiak, K. J., & Gąsecka, A. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10110465 · Cited by 32 · see citing works
Kumar, N., Kumar, B., Ashique, S., Yasmin, S., Venkatesan, K., Islam, A., Ghosh, S., Sahu, A., Bhui, U., & Ansari, M. Y. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112050 · Cited by 27 · see citing works
Giorgino, F., Caruso, I., Moellmann, J., & Lehrke, M. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154045 · Cited by 26 · see citing works
Giannakogeorgou, A., & Roden, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17848 · Cited by 30 · see citing works
Broader Perspective on Atherosclerosis—Selected Risk Factors, Biomarkers, and Therapeutic Approach
Fularski, P., Czarnik, W., Dąbek, B., Lisińska, W., Radzioch, E., Witkowska, A., Młynarska, E., Rysz, J., & Franczyk, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105212 · Cited by 26 · see citing works
Uneda, K., Kawai, Y., Yamada, T., Kinguchi, S., Azushima, K., Kanaoka, T., Toya, Y., Wakui, H., & Tamura, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-89620-7 · Cited by 25 · see citing works
Tandon, S., Ayis, S. A., Hopkins, D. L., Harding, S., & Stadler, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14221 · Cited by 24 · see citing works
Gómez‐Huelgas, R., Sanz‐Cánovas, J., Cobos-Palacios, L., Sampalo, A. L., & Perez-Belmonte, L. M. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.11.008 · Cited by 26 · see citing works
Han, K. A., Kim, Y. H., Kim, D. M., Lee, B., Chon, S., Sohn, T. S., Jeong, I., Hong, E., Son, J. W., Nah, J. J., et al. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0315 · Cited by 24 · see citing works
Goldenberg, R. M., Ahooja, V., Clemens, K. K., Gilbert, J. D., Poddar, M., & Verma, S. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.09.005 · Cited by 23 · see citing works
İmre, E., Günhan, H. G., Erel, P., & Üstay, Ö. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.21.03465-5 · Cited by 23 · see citing works
Shi, F., Li, H., Shen, L., Fu, J., Ma, J., Gu, Z., & Lin, H. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14452 · Cited by 23 · see citing works
Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction: Role of Obesity
Dhore-Patil, A., Thannoun, T., Samson, R., & Jemtel, T. H. L. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2021.785879 · Cited by 25 · see citing works
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors and underlying mechanisms
Kashihara, N., Kidokoro, K., & Kanda, E. (2019) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000561 · Cited by 24 · see citing works
Empagliflozin rescues lifespan and liver senescence in naturally aged mice
Long, J., Ren, Z., Duan, Y., Tao, W., Li, X., Li, S., Li, K., Huang, Q., Chen, J., Yang, M., et al. (2024) · GeroScience · doi:10.1007/s11357-024-01250-9 · Cited by 23 · see citing works
Heymsfield, S. B., Raji, A., Gallo, S., Liu, J., Pong, A., Hannachi, H., & Terra, S. G. (2020) · Obesity · doi:10.1002/oby.22748 · Cited by 21 · see citing works
Hurren, K. M., & Dunham, M. W. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1494727 · Cited by 20 · see citing works
Sundra, T., Knowles, E., Rendle, D. I., Kelty, E. A., Lester, G. D., & Rossi, G. (2024) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2024.106894 · Cited by 20 · see citing works
SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review
Kansara, A., Mubeen, F., & Shakil, J. (2022) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1120 · Cited by 22 · see citing works
Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Kuchay, M. S., Farooqui, K. J., Mishra, S. K., & Mithal, A. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_479 · Cited by 20 · see citing works
Steven, S., Kuntić, M., Münzel, T. F., & Daiber, A. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100082 · Cited by 20 · see citing works
Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes
Papakitsou, I., Vougiouklakis, G., Elisaf, M., & Filippatos, T. D. (2019) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s172353 · Cited by 18 · see citing works
Rainkie, D. C., Abedini, Z. S., & Abdelkader, N. N. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243091 · Cited by 16 · see citing works
Hanson, P., Randeva, H. S., Cuthbertson, D. J., O'Hare, P. J., Parsons, N., Chatha, K. K., Reidy, G., Weickert, M. O., & Barber, T. M. (2022) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.381 · Cited by 15 · see citing works
Yang, Y., Min, K. W., Park, S., Kim, K., Yu, J. M., Hong, E., Cho, S., Won, K. C., Kim, Y. H., Oh, S., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15080 · Cited by 16 · see citing works
Cardiovascular effects and mechanisms of sodium‐glucose cotransporter‐2 inhibitors
Yang, F., Meng, R., & Zhu, D. (2020) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2020.07.002 · Cited by 16 · see citing works
Hinton, W., Feher, M. D., Munro, N. M., Joy, M., & de Lusignan, S. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01316-4 · Cited by 16 · see citing works
Hussain, M., Babar, M. Z. M., Tariq, S., Ahmad, M. I., & Akhtar, L. (2021) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-021-00980-2 · Cited by 15 · see citing works
Instituting a successful discharge plan for patients with type 2 diabetes: challenges and solutions
Demidowich, A. P., Batty, K., & Zilbermint, M. (2022) · Diabetes Spectrum · doi:10.2337/dsi22-0013 · Cited by 15 · see citing works
Doiron, J. E., Xia, H., Yu, X., Nevins, A., LaPenna, K. B., Sharp, T. E., Goodchild, T. T., Allerton, T. D., Elgazzaz, M., Lazartigues, E. D., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16493 · Cited by 14 · see citing works
Kotsis, V., Jordan, J., Stabouli, S., Antza, C., Micić, D., Jelaković, B., Schlaich, M. P., Nilsson, P. M., Kreutz, R. H., Mancia, G., et al. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002279 · Cited by 14 · see citing works
Ojha, U., Reyes, L. M., Eyenga, F., Oumbe, D., Watkowska, J., & Saint-Jacques, H. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00486-6 · Cited by 15 · see citing works
Obesity and heart failure: exploring the cardiometabolic axis
Rayner, J. J., Abdesselam, I., Pan, J., Lewis, A., & Rider, O. J. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf090 · Cited by 14 · see citing works
Dong, M., Chen, H., Wen, S., Yuan, Y., Yang, L.-L., Li, Y.-Y., Yuan, X.-L., Xu, D.-X., & Zhou, L.-G. (2023) · Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy · doi:10.2147/dmso.s399367 · Cited by 11 · see citing works
Self-citationRajeev, S. P., Roberts, C. A., Brown, E. E., Sprung, V. S., Harrold, J. A., Halford, J. C. G., Stančák, A., Boyland, E. J., Kemp, G. J., Perry, J., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15257 · Cited by 14 · see citing works
Dalem, J. D. R.-V., Werkman, N. C. C., van den Bergh, J. P., Rossi, B., Viggers, R., Eastell, R., Burden, A. M., Stehouwer, C. D. A., Klungel, O. H., Brouwers, M. C. G. J., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109993 · Cited by 13 · see citing works
Yalçın, N., Aktaş, S., Uyar, S., & Koca, N. (2025) · Life · doi:10.3390/life15050722 · Cited by 13 · see citing works
Gliozzi, M., Macrì, R., Coppoletta, A. R., Musolino, V., Carresi, C., Scicchitano, M., Bosco, F., Guarnieri, L., Cardamone, A., Ruga, S., et al. (2022) · Nutrients · doi:10.3390/nu14183737 · Cited by 13 · see citing works
Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure
Kao, T., & Huang, C. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1086672 · Cited by 12 · see citing works
Obesity-Related Glomerulopathy: Epidemiology, Pathogenesis, and Current Treatments
Yang, X., Bayliss, G. P., & Zhuang, S. (2024) · Integrative Medicine in Nephrology and Andrology · doi:10.1097/imna-d-24-00011 · Cited by 11 · see citing works
Wu, Q., Zheng, T., Li, S.-Z., Chen, J.-A., Xie, Z., Lai, J., Zeng, J., Lin, J.-T., Huang, J.-S., & Lin, M.-H. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00810-3 · Cited by 11 · see citing works
Current Approaches in Diabetes Treatment and Other Strategies to Reach Normoglycemia
Sirhan, W., & Piran, R. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200716113813 · Cited by 11 · see citing works
Günhan, H. G. (2020) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2020.59 · Cited by 10 · see citing works
Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure
Shah, K., & Fang, J. C. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052120-014725 · Cited by 12 · see citing works
Fardman, A., Kodesh, A., Siegel, A. J., Segev, A., Regev, E., Maor, E., Berkovitch, A., Kuperstein, R., Morgan, A., Nahum, E., et al. (2024) · Artificial Organs · doi:10.1111/aor.14733 · Cited by 10 · see citing works
Chen, J., Peng, Y., Chen, C.-S., Tseng, C., Chen, P.-C., Lee, T.-I., Lu, Y.-C., Yang, Y., Lin, C., Hung, Y.-J., et al. (2020) · PeerJ · doi:10.7717/peerj.9998 · Cited by 10 · see citing works
Gliflozins in hypertension: basic mechanisms and clinical insights
Rieg, T., Liu, R., & Staruschenko, A. (2025) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00119.2025 · Cited by 9 · see citing works
Shi, Y., Si, Y., Fu, R., Zhang, M., Jiang, K., Dai, W., Shen, J., Li, X., & Yuan, Y. (2022) · Endokrynologia Polska · doi:10.5603/ep.a2021.0102 · Cited by 9 · see citing works
Roy, S., & Majumder, A. (2019) · Cureus · doi:10.7759/cureus.4674 · Cited by 9 · see citing works
Possible Mechanisms of Action of SGLT2 Inhibitors in Heart Failure
Martins, C. N. G., Bau, A. A., da Silva, L. M., & Coelho‐Filho, O. R. (2021) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20210007 · Cited by 9 · see citing works
- Authors
- Cai, X., Yang, W., Gao, X., Chen, Y., Zhou, L., Zhang, S., Han, X., & Ji, L.
- Affiliations
- Peking University People's Hospital (CN)
- Corresponding author
- Ji, Linong
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2017-11-22
- Volume
- 26
- Issue
- 1
- Pages
- 70-80
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- OpenAlex
- W2768862775
- Semantic Scholar
- 16abcdc081dce9cc61218dc3d41bb10450e26478
- Cited by
- 181
- References
- 76
- Citations by year
- 2026: 7 · 2025: 24 · 2024: 21 · 2023: 18 · 2022: 28 · 2021: 31 · 2020: 26 · 2019: 17 · 2018: 8 · 2014: 1
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Obesity (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- SGLT2 inhibitors, type 2 diabetes, weight loss, dapagliflozin, canagliflozin, empagliflozin, ipragliflozin, tofogliflozin, luseogliflozin, dosage dependence
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Weight Loss
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
